Media coverage about Achaogen (NASDAQ:AKAO) has been trending somewhat negative this week, according to Accern Sentiment. The research group ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Achaogen earned a media sentiment score of -0.01 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 46.7656378419236 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the media headlines that may have impacted Accern’s rankings:
Several equities analysts have commented on the stock. Zacks Investment Research raised shares of Achaogen from a “sell” rating to a “hold” rating in a report on Wednesday, May 9th. SunTrust Banks decreased their target price on shares of Achaogen to $16.00 and set a “buy” rating on the stock in a report on Friday, May 4th. HC Wainwright reissued a “buy” rating and issued a $29.00 target price (up from $19.00) on shares of Achaogen in a report on Monday, April 30th. BidaskClub raised shares of Achaogen from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. Finally, William Blair reissued an “outperform” rating on shares of Achaogen in a report on Wednesday, February 28th. Four analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $22.67.
Shares of Achaogen traded down $0.33, hitting $12.56, during midday trading on Thursday, Marketbeat Ratings reports. 24,760 shares of the company traded hands, compared to its average volume of 1,319,392. The firm has a market capitalization of $576.53 million, a PE ratio of -3.95 and a beta of 1.02. The company has a current ratio of 7.01, a quick ratio of 7.01 and a debt-to-equity ratio of 0.24. Achaogen has a 12 month low of $12.89 and a 12 month high of $13.14.
Achaogen (NASDAQ:AKAO) last announced its quarterly earnings results on Friday, May 4th. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by ($0.17). Achaogen had a negative net margin of 2,384.08% and a negative return on equity of 97.86%. The company had revenue of $2.14 million for the quarter, compared to the consensus estimate of $1.25 million. research analysts anticipate that Achaogen will post -3.43 earnings per share for the current year.
In other news, major shareholder Robert W. Duggan purchased 976,880 shares of the company’s stock in a transaction dated Thursday, May 3rd. The shares were purchased at an average price of $11.33 per share, for a total transaction of $11,068,050.40. Following the transaction, the insider now owns 8,027,627 shares of the company’s stock, valued at $90,953,013.91. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, major shareholder Robert W. Duggan purchased 527,396 shares of the company’s stock in a transaction dated Friday, March 2nd. The stock was purchased at an average price of $10.31 per share, for a total transaction of $5,437,452.76. Following the transaction, the insider now directly owns 5,697,752 shares in the company, valued at approximately $58,743,823.12. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 2,545,730 shares of company stock worth $29,680,700 and have sold 10,989 shares worth $124,967. 7.80% of the stock is owned by company insiders.
Achaogen Company Profile
Achaogen, Inc, a late-stage biopharmaceutical company, focusses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae.
Receive News & Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related companies with MarketBeat.com's FREE daily email newsletter.